What is Nectar?
Nectar operates at the intersection of clinical medicine and digital health, offering a comprehensive suite of services designed to address the growing prevalence of allergies, asthma, and eczema. By integrating traditional medical testing with flexible, patient-centric treatment plans, the company has established a robust market position in the New York City metropolitan area. Their service architecture includes advanced immunotherapy options and accessible digital consultations, catering to both pediatric and adult demographics. By accepting major insurance providers and streamlining the appointment process, Nectar effectively lowers the barrier to entry for specialized allergy care, positioning itself as a modern alternative to traditional, fragmented clinical practices.
How much funding has Nectar raised?
Nectar has raised a total of $16.5M across 1 funding round:
Series A
$16.5M
Series A (2022): $16.5M with participation from Juxtapose, The Obvious, and Harmony Partners
Key Investors in Nectar
Juxtapose
An inception-stage investment firm that specializes in building industry-transforming businesses from the ground up by partnering with experienced entrepreneurial operators.
The Obvious
A creative and design firm that provides strategic marketing and communication services, helping companies translate complex ideas into visually distinctive assets.
Harmony Partners
A venture capital firm with over 30 years of experience, focusing on providing flexible financing and strategic support to help innovative companies scale during expansion rounds.
What's next for Nectar?
With the successful completion of this major enterprise-level funding, Nectar is well-positioned to scale its operational footprint and enhance its digital infrastructure. The strategic deployment of this capital will likely focus on expanding the company's reach beyond its current geographic base and refining its proprietary treatment delivery systems. As the firm transitions from its initial growth phase into a more mature operational cycle, the focus will shift toward optimizing patient outcomes through data-driven care protocols and increasing the efficiency of its immunotherapy distribution. Investors are expected to monitor the company's ability to maintain high-quality clinical standards while aggressively capturing market share in the competitive allergy and immunology sector.
See full Nectar company page
